Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 102

1.

Model-Informed Dosing of Venetoclax in Healthy Subjects: An Exposure-Response Analysis.

Dave N, Gopalakrishnan S, Mensing S, Salem AH.

Clin Transl Sci. 2019 Jul 3. doi: 10.1111/cts.12665. [Epub ahead of print]

PMID:
31268229
2.

Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis.

Agarwal S, Gopalakrishnan S, Mensing S, Potluri J, Hayslip J, Kirschbrown W, Friedel A, Menon R, Salem AH.

Hematol Oncol. 2019 Jun 28. doi: 10.1002/hon.2646. [Epub ahead of print]

PMID:
31251400
3.

Bayesian Population Model of the Pharmacokinetics of Venetoclax in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from the Phase III MURANO Study.

Deng R, Gibiansky L, Lu T, Agarwal P, Ding H, Li X, Kshirsagar S, Lu D, Li C, Girish S, Wang J, Boyer M, Humphrey K, Freise KJ, Salem AH, Seymour JF, Kater AP, Miles D.

Clin Pharmacokinet. 2019 Jun 18. doi: 10.1007/s40262-019-00788-8. [Epub ahead of print]

PMID:
31209657
4.

Pharmacokinetics of the BCL-2 Inhibitor Venetoclax in Subjects with Hepatic Impairment.

Salem AH, Dave N, Marbury T, Hu B, Miles D, Agarwal SK, Bueno OF, Menon RM.

Clin Pharmacokinet. 2019 Aug;58(8):1091-1100. doi: 10.1007/s40262-019-00746-4.

PMID:
30949874
5.

An unconventional RNA-based thermosensor within the 5' UTR of Staphylococcus aureus cidA.

Hussein H, Fris ME, Salem AH, Wiemels RE, Bastock RA, Righetti F, Burke CA, Narberhaus F, Carroll RK, Hassan NS, Mohamed SA, Fahmy AS, Murphy ER.

PLoS One. 2019 Apr 1;14(4):e0214521. doi: 10.1371/journal.pone.0214521. eCollection 2019.

6.

Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study.

Wei AH, Strickland SA Jr, Hou JZ, Fiedler W, Lin TL, Walter RB, Enjeti A, Tiong IS, Savona M, Lee S, Chyla B, Popovic R, Salem AH, Agarwal S, Xu T, Fakouhi KM, Humerickhouse R, Hong WJ, Hayslip J, Roboz GJ.

J Clin Oncol. 2019 May 20;37(15):1277-1284. doi: 10.1200/JCO.18.01600. Epub 2019 Mar 20.

PMID:
30892988
7.

Power determination during drug development: Is optimizing the sample size based on exposure-response analyses underutilized?

Jones AK, Salem AH, Freise KJ.

CPT Pharmacometrics Syst Pharmacol. 2019 Jan 18. doi: 10.1002/psp4.12380. [Epub ahead of print]

8.

Upregulation of Circulating Cardiomyocyte-Enriched miR-1 and miR-133 Associate with the Risk of Coronary Artery Disease in Type 2 Diabetes Patients and Serve as Potential Biomarkers.

Al-Muhtaresh HA, Salem AH, Al-Kafaji G.

J Cardiovasc Transl Res. 2019 Aug;12(4):347-357. doi: 10.1007/s12265-018-9857-2. Epub 2019 Jan 4.

PMID:
30610670
9.

Validating the modified System for Evaluation of Teaching Qualities: a teaching quality assessment instrument.

Ansari AA, Arekat MR, Salem AH.

Adv Med Educ Pract. 2018 Nov 30;9:881-886. doi: 10.2147/AMEP.S181094. eCollection 2018.

10.

Distinct HLA class I and II genotypes and haplotypes are associated with multiple sclerosis in Bahrain.

Al-Nashmi M, Taha S, Salem AH, Alsharoqi I, Bakhiet M.

Biomed Rep. 2018 Dec;9(6):531-539. doi: 10.3892/br.2018.1164. Epub 2018 Oct 24.

11.

Effect of Azithromycin on Venetoclax Pharmacokinetics in Healthy Volunteers: Implications for Dosing Venetoclax with P-gp Inhibitors.

Agarwal SK, Tong B, Bueno OF, Menon RM, Salem AH.

Adv Ther. 2018 Nov;35(11):2015-2023. doi: 10.1007/s12325-018-0793-y. Epub 2018 Sep 27.

PMID:
30264382
12.

Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study.

de Vos S, Swinnen LJ, Wang D, Reid E, Fowler N, Cordero J, Dunbar M, Enschede SH, Nolan C, Petrich AM, Ross JA, Salem AH, Verdugo M, Agarwal S, Zhou L, Kozloff M, Nastoupil LJ, Flowers CR.

Ann Oncol. 2018 Sep 1;29(9):1932-1938. doi: 10.1093/annonc/mdy256.

13.

Two-stage anaerobic fermentation process for bio-hydrogen and bio-methane production from pre-treated organic wastes.

Salem AH, Mietzel T, Brunstermann R, Widmann R.

Bioresour Technol. 2018 Oct;265:399-406. doi: 10.1016/j.biortech.2018.06.017. Epub 2018 Jun 8.

PMID:
29933187
14.

Statins enhance efficacy of venetoclax in blood cancers.

Lee JS, Roberts A, Juarez D, Vo TT, Bhatt S, Herzog LO, Mallya S, Bellin RJ, Agarwal SK, Salem AH, Xu T, Jia J, Li L, Hanna JR, Davids MS, Fleischman AG, O'Brien S, Lam LT, Leverson JD, Letai A, Schatz JH, Fruman DA.

Sci Transl Med. 2018 Jun 13;10(445). pii: eaaq1240. doi: 10.1126/scitranslmed.aaq1240.

15.

Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial.

Stilgenbauer S, Eichhorst B, Schetelig J, Hillmen P, Seymour JF, Coutre S, Jurczak W, Mulligan SP, Schuh A, Assouline S, Wendtner CM, Roberts AW, Davids MS, Bloehdorn J, Munir T, Böttcher S, Zhou L, Salem AH, Desai M, Chyla B, Arzt J, Kim SY, Verdugo M, Gordon G, Hallek M, Wierda WG.

J Clin Oncol. 2018 Jul 1;36(19):1973-1980. doi: 10.1200/JCO.2017.76.6840. Epub 2018 May 1. Erratum in: J Clin Oncol. 2019 Sep 1;37(25):2299.

PMID:
29715056
16.

Use of depth of response to predict progression-free survival in relapsed or refractory multiple myeloma: Evaluation of results from 102 clinical trials.

Mangal N, Salem AH, Menon RM, Freise KJ.

Hematol Oncol. 2018 Apr 19. doi: 10.1002/hon.2514. [Epub ahead of print]

PMID:
29672885
17.

Impact of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical pharmacokinetics.

Freise KJ, Hu B, Salem AH.

Eur J Clin Pharmacol. 2018 Apr;74(4):413-421. doi: 10.1007/s00228-017-2403-3. Epub 2018 Jan 4.

PMID:
29302721
18.

Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.

Jones JA, Mato AR, Wierda WG, Davids MS, Choi M, Cheson BD, Furman RR, Lamanna N, Barr PM, Zhou L, Chyla B, Salem AH, Verdugo M, Humerickhouse RA, Potluri J, Coutre S, Woyach J, Byrd JC.

Lancet Oncol. 2018 Jan;19(1):65-75. doi: 10.1016/S1470-2045(17)30909-9. Epub 2017 Dec 12.

19.

Pharmacokinetics of the BCL-2 Inhibitor Venetoclax in Healthy Chinese Subjects.

Cheung TT, Salem AH, Menon RM, Munasinghe WP, Bueno OF, Agarwal SK.

Clin Pharmacol Drug Dev. 2018 May;7(4):435-440. doi: 10.1002/cpdd.395. Epub 2017 Oct 23.

PMID:
29058801
20.

Clinical evaluation of P-glycoprotein inhibition by venetoclax: a drug interaction study with digoxin.

Chiney MS, Menon RM, Bueno OF, Tong B, Salem AH.

Xenobiotica. 2018 Sep;48(9):904-910. doi: 10.1080/00498254.2017.1381779. Epub 2017 Oct 13.

PMID:
29027832
21.

Model-based meta-analysis of progression-free survival in non-Hodgkin lymphoma patients.

Li M, Dave N, Salem AH, Freise KJ.

Medicine (Baltimore). 2017 Sep;96(35):e7988. doi: 10.1097/MD.0000000000007988. Review.

22.

Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM.

Moreau P, Chanan-Khan A, Roberts AW, Agarwal AB, Facon T, Kumar S, Touzeau C, Punnoose EA, Cordero J, Munasinghe W, Jia J, Salem AH, Freise KJ, Leverson JD, Enschede SH, Ross JA, Maciag PC, Verdugo M, Harrison SJ.

Blood. 2017 Nov 30;130(22):2392-2400. doi: 10.1182/blood-2017-06-788323. Epub 2017 Aug 28.

23.

Exposure-response evaluations of venetoclax efficacy and safety in patients with non-Hodgkin lymphoma.

Parikh A, Gopalakrishnan S, Freise KJ, Verdugo ME, Menon RM, Mensing S, Salem AH.

Leuk Lymphoma. 2018 Apr;59(4):871-879. doi: 10.1080/10428194.2017.1361024. Epub 2017 Aug 10.

PMID:
28797193
24.

Response Rates as Predictors of Overall Survival: A Meta-Analysis of Acute Myeloid Leukemia Trials.

Agarwal SK, Mangal N, Menon RM, Freise KJ, Salem AH.

J Cancer. 2017 Jun 3;8(9):1562-1567. doi: 10.7150/jca.18686. eCollection 2017.

25.

Relationship between response rates and median progression-free survival in non-Hodgkin's lymphoma: A meta-analysis of published clinical trials.

Mangal N, Salem AH, Li M, Menon R, Freise KJ.

Hematol Oncol. 2018 Feb;36(1):37-43. doi: 10.1002/hon.2463. Epub 2017 Jul 14.

PMID:
28707346
26.

Pharmacokinetics of venetoclax in patients with 17p deletion chronic lymphocytic leukemia.

Salem AH, Dunbar M, Agarwal SK.

Anticancer Drugs. 2017 Sep;28(8):911-914. doi: 10.1097/CAD.0000000000000522.

PMID:
28562380
27.

Moving Beyond Maximum Tolerated Dose for Targeted Oncology Drugs: Use of Clinical Utility Index to Optimize Venetoclax Dosage in Multiple Myeloma Patients.

Freise KJ, Jones AK, Verdugo ME, Menon RM, Maciag PC, Salem AH.

Clin Pharmacol Ther. 2017 Dec;102(6):970-976. doi: 10.1002/cpt.712. Epub 2017 May 26.

PMID:
28419431
28.

Management of Venetoclax-Posaconazole Interaction in Acute Myeloid Leukemia Patients: Evaluation of Dose Adjustments.

Agarwal SK, DiNardo CD, Potluri J, Dunbar M, Kantarjian HM, Humerickhouse RA, Wong SL, Menon RM, Konopleva MY, Salem AH.

Clin Ther. 2017 Feb;39(2):359-367. doi: 10.1016/j.clinthera.2017.01.003. Epub 2017 Feb 1.

PMID:
28161120
29.

Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.

Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, Puvvada S, Kipps TJ, Anderson MA, Salem AH, Dunbar M, Zhu M, Peale F, Ross JA, Gressick L, Desai M, Kim SY, Verdugo M, Humerickhouse RA, Gordon GB, Gerecitano JF.

J Clin Oncol. 2017 Mar 10;35(8):826-833. doi: 10.1200/JCO.2016.70.4320. Epub 2017 Jan 17.

30.

Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model.

Freise KJ, Shebley M, Salem AH.

J Clin Pharmacol. 2017 Jun;57(6):796-804. doi: 10.1002/jcph.858. Epub 2017 Jan 4.

PMID:
28052338
31.

Metabolism and Disposition of a Novel B-Cell Lymphoma-2 Inhibitor Venetoclax in Humans and Characterization of Its Unusual Metabolites.

Liu H, Michmerhuizen MJ, Lao Y, Wan K, Salem AH, Sawicki J, Serby M, Vaidyanathan S, Wong SL, Agarwal S, Dunbar M, Sydor J, de Morais SM, Lee AJ.

Drug Metab Dispos. 2017 Mar;45(3):294-305. doi: 10.1124/dmd.116.071613. Epub 2016 Dec 19.

PMID:
27993930
32.

Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy.

Freise KJ, Jones AK, Menon RM, Verdugo ME, Humerickhouse RA, Awni WM, Salem AH.

Hematol Oncol. 2017 Dec;35(4):679-684. doi: 10.1002/hon.2373. Epub 2016 Dec 16.

PMID:
27982454
33.

Evaluation of the Pharmacokinetic Interaction between Venetoclax, a Selective BCL-2 Inhibitor, and Warfarin in Healthy Volunteers.

Salem AH, Hu B, Freise KJ, Agarwal SK, Sidhu DS, Wong SL.

Clin Drug Investig. 2017 Mar;37(3):303-309. doi: 10.1007/s40261-016-0485-9.

PMID:
27910036
34.

Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma.

Agarwal SK, Salem AH, Danilov AV, Hu B, Puvvada S, Gutierrez M, Chien D, Lewis LD, Wong SL.

Br J Clin Pharmacol. 2017 Apr;83(4):846-854. doi: 10.1111/bcp.13175. Epub 2017 Jan 18.

35.

Morphology of Anterolateral Ligament of the Knee: A Cadaveric Observation with Clinical Insight.

Potu BK, Salem AH, Abu-Hijleh MF.

Adv Med. 2016;2016:9182863. Epub 2016 Oct 25.

36.

Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia.

Freise KJ, Jones AK, Eckert D, Mensing S, Wong SL, Humerickhouse RA, Awni WM, Salem AH.

Clin Pharmacokinet. 2017 May;56(5):515-523. doi: 10.1007/s40262-016-0453-9.

PMID:
27638334
37.

Venetoclax does not prolong the QT interval in patients with hematological malignancies: an exposure-response analysis.

Freise KJ, Dunbar M, Jones AK, Hoffman D, Enschede SL, Wong S, Salem AH.

Cancer Chemother Pharmacol. 2016 Oct;78(4):847-53. doi: 10.1007/s00280-016-3144-1. Epub 2016 Sep 1.

PMID:
27586967
38.

Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma.

Salem AH, Agarwal SK, Dunbar M, Enschede SL, Humerickhouse RA, Wong SL.

J Clin Pharmacol. 2017 Apr;57(4):484-492. doi: 10.1002/jcph.821. Epub 2016 Nov 15.

PMID:
27558232
39.

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.

Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L, Busman T, McKeegan E, Salem AH, Zhu M, Ricker JL, Blum W, DiNardo CD, Kadia T, Dunbar M, Kirby R, Falotico N, Leverson J, Humerickhouse R, Mabry M, Stone R, Kantarjian H, Letai A.

Cancer Discov. 2016 Oct;6(10):1106-1117. Epub 2016 Aug 12.

40.

Circulating endothelium-enriched microRNA-126 as a potential biomarker for coronary artery disease in type 2 diabetes mellitus patients.

Al-Kafaji G, Al-Mahroos G, Abdulla Al-Muhtaresh H, Sabry MA, Abdul Razzak R, Salem AH.

Biomarkers. 2017 May - Jun;22(3-4):268-278. doi: 10.1080/1354750X.2016.1204004. Epub 2016 Jul 11.

PMID:
27321479
41.

Clinical Predictors of Venetoclax Pharmacokinetics in Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma Patients: a Pooled Population Pharmacokinetic Analysis.

Jones AK, Freise KJ, Agarwal SK, Humerickhouse RA, Wong SL, Salem AH.

AAPS J. 2016 Sep;18(5):1192-1202. doi: 10.1208/s12248-016-9927-9. Epub 2016 May 27.

PMID:
27233802
42.

Effect of Low- and High-Fat Meals on the Pharmacokinetics of Venetoclax, a Selective First-in-Class BCL-2 Inhibitor.

Salem AH, Agarwal SK, Dunbar M, Nuthalapati S, Chien D, Freise KJ, Wong SL.

J Clin Pharmacol. 2016 Nov;56(11):1355-1361. doi: 10.1002/jcph.741.

PMID:
27029823
43.
44.

No Need for Lopinavir Dose Adjustment during Pregnancy: a Population Pharmacokinetic and Exposure-Response Analysis in Pregnant and Nonpregnant HIV-Infected Subjects.

Salem AH, Jones AK, Santini-Oliveira M, Taylor GP, Patterson KB, Nilius AM, Klein CE.

Antimicrob Agents Chemother. 2015 Nov 2;60(1):400-8. doi: 10.1128/AAC.01197-15. Print 2016 Jan.

45.

Lack of association of rs3798220 with small apolipoprotein(a) isoforms and high lipoprotein(a) levels in East and Southeast Asians.

Khalifa M, Noureen A, Ertelthalner K, Bandegi AR, Delport R, Firdaus WJ, Geethanjali FS, Luthra K, Makemaharn O, Pang RW, Salem AH, Sasaki J, Schiefenhoevel W, Lingenhel A, Kronenberg F, Utermann G, Schmidt K.

Atherosclerosis. 2015 Oct;242(2):521-8. doi: 10.1016/j.atherosclerosis.2015.07.015. Epub 2015 Jul 15.

PMID:
26302166
46.

Thrombomodulin gene proximal promoter polymorphisms in premature acute coronary syndrome patients in Bahrain.

Azme AA, Shome DK, Salem AH, Fadhli SA, Bannay RA, Jaradat A.

Blood Coagul Fibrinolysis. 2015 Dec;26(8):919-24. doi: 10.1097/MBC.0000000000000361.

PMID:
26226255
48.

Relationships between the quality of blended learning experience, self-regulated learning, and academic achievement of medical students: a path analysis.

Kassab SE, Al-Shafei AI, Salem AH, Otoom S.

Adv Med Educ Pract. 2015 Jan 8;6:27-34. doi: 10.2147/AMEP.S75830. eCollection 2015.

49.

Pharmacokinetic enhancement in HIV antiretroviral therapy: a comparison of ritonavir and cobicistat.

Renjifo B, van Wyk J, Salem AH, Bow D, Ng J, Norton M.

AIDS Rev. 2015 Jan-Mar;17(1):37-46. Review.

PMID:
25586481
50.

A novel ritonavir paediatric powder formulation is bioequivalent to ritonavir oral solution with a similar food effect.

Salem AH, Chiu YL, Valdes JM, Nilius AM, Klein CE.

Antivir Ther. 2015;20(4):425-32. doi: 10.3851/IMP2932. Epub 2015 Jan 9.

PMID:
25573904

Supplemental Content

Loading ...
Support Center